1st treatment for EGFR+ NSCLC with exon 19 deletions or exon 21 L858R mutations
Your care team will continuously support you throughout treatment
It’s important to tell your care team about side effects right away, if you:
- First experience of side effects
- Feel that the side effects are affecting daily activities
- Have been treating side effects according to your doctor’s instructions but they do not improve
Your experience may vary. If you experience any of the following symptoms of side effects, tell your doctor right away.
Possible serious side effects of RYBREVANT® + LAZCLUZE™ include:
Infusion-related reactions
-related reactions are common with RYBREVANT® and can be severe or serious. Tell your doctor right away if you experience infusion-related reactions (shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, vomiting), with most occurring during the first infusion. Your treatment team may adjust or pause your infusion dosing and timing to help manage any reactions that may occur.
Lung problems
You may experience lung problems that may lead to death. Signs and symptoms of lung problems may be similar to those of lung cancer. Some of the common signs to watch out for are shortness of breath, cough, or fever. Tell your doctor right away if you have any new or worsening lung problems.
Blood clots (“venous thromboembolism” or “VTE”)
When RYBREVANT® is given in combination with LAZCLUZE™, blood clots are a serious but common side effect. You may experience blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Tell your doctor right away if you notice swelling, pain, or tenderness in the leg; sudden unexplained chest pain; or shortness of breath. Your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment.
Skin problems
You may experience severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Tell your doctor right away if you have any skin reactions. They may treat you with medicine(s) or send you to see a skin specialist (dermatologist). It may be helpful to proactively take steps to minimize any discomfort. Please read the proactive steps you can take here.
Eye problems
You may experience eye problems, which may include eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. Your doctor may refer you to an eye specialist (ophthalmologist). You should not use contact lenses until your eye symptoms are checked by a healthcare provider.
Harm to your unborn baby
RYBREVANT® + LAZCLUZE™ can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. If you are able to become pregnant you should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT® and during treatment and for 3 weeks after your last dose of LAZCLUZE™. Tell your healthcare provider right away if you become pregnant or think you might be pregnant.
If your partner is able to become pregnant, you should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.
Most common side effects of RYBREVANT® + LAZCLUZE™
- Rash
- Infected skin around the nail
- Infusion-related reaction (amivantamab)
- Muscle and joint pain
- Sores in the mouth
- Swelling of hands, ankles, feet, face, or all of your body
- Unusual feeling in the skin (such as tingling or crawling feeling)
- Feeling very tired
- Diarrhea
- Constipation
- COVID-19
- Dry skin
- Bleeding
- Decreased appetite
- Itchy skin
- Nausea
- Changes in certain blood tests
Your care team can help prevent or manage side effects to help you stay on treatment.
Always tell your care team if you experience side effects, so you can help manage them together.
Treatment brochure
A general guide to RYBREVANT® + LAZCLUZE™ for the first treatment of NSCLC with common EGFR mutations.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
